Literature DB >> 25847281

Oxygen uptake kinetics and exercise capacity in children with cystic fibrosis.

Jeremy Fielding1, Lucy Brantley1, Nichole Seigler1, Katie T McKie2, Gareth W Davison3, Ryan A Harris1,3.   

Abstract

Exercise capacity, an objective measure of exercise intolerance, is known to predict quality of life and mortality in cystic fibrosis (CF). The mechanisms for exercise intolerance in patients with cystic fibrosis (CF), however, have yet to be fully elucidated. Accordingly, this study sought to investigate oxygen uptake kinetics and the impact of fat-free mass (FFM) on exercise capacity in young patients with CF. 16 young patients with CF (age 13 ± 4 years; 10 female) and 15 matched controls (age 14 ± 3 years; nine female) participated. Pulmonary function and a maximal exercise test on a cycle ergometer using the Godfrey protocol were performed. Exercise capacity (VO2 peak), VO2 response time (VO2 RT), and functional VO2 gain (ΔVO2 /ΔWR) were all determined. Lung function was the only demographic parameter significantly lower (P < 0.05) in CF compared to controls. Exercise capacity was lower in CF (P < 0.014) only when VO2 peak was normalized for FFM (43.5 ± 7.7 vs. 50.6 ± 7.4 ml/kg-FFM/min) or expressed as % predicted (70.1 ± 14.3 vs. 85.4 ± 16.0%). The VO2 RT was slower (36.1 ± 15.1 vs. 25.0 ± 12.4 sec; P = 0.03) and the ΔVO2 /ΔWR slope was lower (8.4 ± 3 ml/min/watt vs. 10.1 ± 1.4 ml/min/watt; P = 0.02) in patients compared to controls, respectively. In conclusion, a delayed VO2 response time coupled with the lower functional VO2 gain (ΔVO2 /ΔWR) suggest that young patients with CF have impairment in oxygen transport and oxygen utilization by the muscles. These data in addition to differences in VO2 peak normalized for FFM provide some insight that muscle mass and muscle metabolism contribute to exercise intolerance in CF.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Exercise capacity; body composition; oxygen uptake; patients; young

Mesh:

Year:  2015        PMID: 25847281     DOI: 10.1002/ppul.23189

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  Evidence of microvascular dysfunction in patients with cystic fibrosis.

Authors:  Paula Rodriguez-Miguelez; Jeffrey Thomas; Nichole Seigler; Reva Crandall; Kathleen T McKie; Caralee Forseen; Ryan A Harris
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-15       Impact factor: 4.733

2.  Blood flow regulation and oxidative stress during submaximal cycling exercise in patients with cystic fibrosis.

Authors:  Matthew A Tucker; Breana Berry; Nichole Seigler; Gareth W Davison; John C Quindry; Dabney Eidson; Kathleen T McKie; Ryan A Harris
Journal:  J Cyst Fibros       Date:  2017-10-12       Impact factor: 5.482

3.  Exercise testing in patients with cystic fibrosis-importance of ventilatory parameters.

Authors:  Matthew A Tucker; Nichole Lee; Paula Rodriguez-Miguelez; Jacob Looney; Reva H Crandall; Caralee Forseen; Kathleen T McKie; Ryan A Harris
Journal:  Eur J Appl Physiol       Date:  2018-10-24       Impact factor: 3.078

4.  Exercise capacity in patients with cystic fibrosis vs. non-cystic fibrosis bronchiectasis.

Authors:  Ronen Bar-Yoseph; Anat Ilivitzki; Dan M Cooper; Michal Gur; Gur Mainzer; Fahed Hakim; Galit Livnat; Zeev Schnapp; George Shalloufeh; Merav Zucker-Toledano; Yael Subar; Lea Bentur
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

5.  The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis.

Authors:  Kevin J Scully; Laura T Jay; Steven Freedman; Gregory S Sawicki; Ahmet Uluer; Joel S Finkelstein; Melissa S Putman
Journal:  Nutrients       Date:  2022-01-12       Impact factor: 5.717

6.  Exercise Intolerance in Cystic Fibrosis: Importance of Skeletal Muscle.

Authors:  Paula Rodriguez-Miguelez; Nichole Seigler; Haruki Ishii; Reva Crandall; Kathleen T McKie; Caralee Forseen; Ryan A Harris
Journal:  Med Sci Sports Exerc       Date:  2021-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.